- Home
- RNAZ
as 05-30-2025 4:00pm EST
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 281.3K | IPO Year: | 2021 |
| Target Price: | $280.00 | AVG Volume (30 days): | 107.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -469.07 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.15 - $1663.20 | Next Earning Date: | 05-14-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest TransCode Therapeutics Inc. News
RNAZ Breaking Stock News: Dive into RNAZ Ticker-Specific Updates for Smart Investing
PR Newswire
4 days ago
TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board
PR Newswire
24 days ago
TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported
PR Newswire
a month ago
TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split
PR Newswire
a month ago
TransCode Therapeutics Announces 1-for-28 Reverse Stock Split
NewMediaWire
a month ago
IBN Coverage: TransCode Therapeutics (NASDAQ: RNAZ) Advances Phase 1a Trial of RNA Cancer Therapy TTX-MC138
PR Newswire
a month ago
TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer
Benzinga
a month ago
EXCLUSIVE: TransCode Therapeutics Reports Progress In Early-Stage Study For Lead Cancer Drug
PR Newswire
a month ago
TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting
Share on Social Networks:
Disclaimer
The information presented on this page, "RNAZ TransCode Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.